奥替康唑是一种新型口服生物可利用的真菌细胞色素 P450酶 51 (CYP51)选择性抑制剂，在治疗复发性外阴阴道念珠菌病(RVVC) 患者中表现出良好的疗效。该药物以Vivjoa为品牌销售，由 Mycovia Pharmaceuticals 开发，并于 2022 年 4 月获得美国食品药品监督管理局(US FDA)的药用 ...

奥替康唑是一种新型口服生物可利用的真菌细胞色素 P450酶 51 (CYP51)选择性抑制剂，在治疗复发性外阴阴道念珠菌病(RVVC) 患者中表现出良好的疗效。 该药物以Vivjoa为品牌销售，由 Mycovia Pharmaceuticals 开发，并于 2022 年 4 月获得美国食品药品监督管理局(US FDA)的药用 ...

Moreover, oteseconazole and the two other tetrazoles did not inhibit 11β-HSD2 ... In the adrenals cytochrome-P450 (CYP) and hydroxysteroid dehydrogenase (HSD) enzymes are responsible for the synthesis ...

Oteseconazole is under clinical development by Mycovia Pharmaceuticals and currently in Phase I for Cryptococcal Meningitis. According to GlobalData, Phase I drugs for Cryptococcal Meningitis does not ...

The development of combined organic and on-surface synthesis allows for the fabrication and characterization of organic nanomaterials with atomic precision. Such materials have the potential to ...

Ltd ("Hengrui") has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC).

Ltd ("Hengrui") received approval in June from the National Medical Products Administration for Oteseconazole Capsules, an azole antifungal, indicated for the treatment of severe vulvovaginal ...

("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") received approval in June from the National Medical Products ...